Kraemer, Max
ORCID: 0009-0006-9275-6121, Wirsik, Naita M.
ORCID: 0000-0003-1619-6354, Alakus, Hakan
ORCID: 0000-0002-3889-3276, Schloesser, Hans A.
ORCID: 0000-0002-1304-7719, Fuchs, Hans
ORCID: 0000-0003-4764-8050, Schroeder, Wolfgang
ORCID: 0000-0002-8700-069X, Bruns, Christiane J.
ORCID: 0000-0001-6590-8181, Lyu, Su Ir
ORCID: 0009-0002-4125-6048, Baehr, Friederike, Zander, Thomas
ORCID: 0000-0002-4266-6818 and Quaas, Alexander
ORCID: 0000-0002-3537-6011
(2025).
Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy.
International Journal of Cancer, 157 (12).
pp. 2558-2568.
Wiley.
ISSN 0020-7136
|
PDF
Intl Journal of Cancer - 2025 - Kraemer - Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric.pdf Bereitstellung unter der CC-Lizenz: Creative Commons Attribution. Download (1MB) |
Abstract
Oesophagogastric junction and gastric adenocarcinoma (OGA) are associated with high mortality rates, with 5-year survival rates below 50% in the curative setting. This study evaluates the efficacy of adjuvant chemotherapy (a chemotherapy regimen consisting of docetaxel, oxaliplatin, leucovorin and 5-fluorouracil [FLOT]) in patients with low tumour regression grades (TRG) following neoadjuvant FLOT (>10% viable tumour cells in surgical specimen, TRG 2/3 analogue Becker's classification). Data from all patients who had undergone ≥3 cycles of neoadjuvant FLOT with R0 resection and TRG 2/3 in surgical specimen, diagnosed between 2017 and 2020 at the University of Cologne (n = 134), were analyzed. Patients were categorised into three groups based on the administration of postoperative FLOT: ‘FLOT complete’ (four cycles), ‘FLOT incomplete’ (one to three cycles) and ‘no FLOT’ (0 cycles). Progression-free survival (PFS) and overall survival (OS) were compared. There is a statistically significant PFS advantage for the ‘FLOT complete’ group compared to ‘no FLOT’ (p = .028) in the total patient cohort and a tendency for an OS benefit. In the subgroup of patients with lymph node metastasis in surgical specimen (ypN+ cohort, n = 91), the PFS advantage of ‘FLOT complete’ was diminished and statistically no longer significant, and there is no OS benefit for these patients. However, multivariate analysis confirmed a significant PFS benefit for ‘FLOT complete’ both in the total cohort (p = .011) and in ypN+ patients (p = .018). These findings suggest that full adjuvant FLOT is beneficial even for OGA patients with low tumour regression; however, its efficacy appears reduced in those with lymph node metastasis, warranting further investigation into individualising treatment strategies.
| Item Type: | Article |
| Creators: | Creators Email ORCID ORCID Put Code Baehr, Friederike UNSPECIFIED UNSPECIFIED UNSPECIFIED |
| URN: | urn:nbn:de:hbz:38-805303 |
| Identification Number: | 10.1002/ijc.70048 |
| Journal or Publication Title: | International Journal of Cancer |
| Volume: | 157 |
| Number: | 12 |
| Page Range: | pp. 2558-2568 |
| Number of Pages: | 11 |
| Date: | 15 December 2025 |
| Publisher: | Wiley |
| ISSN: | 0020-7136 |
| Language: | English |
| Faculty: | Faculty of Medicine |
| Divisions: | Faculty of Medicine > Chirurgie > Klinik und Poliklinik für Allgemein-, Viszeral-, Thorax- und Transplantationschirurgie Faculty of Medicine > Innere Medizin > Klinik I für Innere Medizin - Hämatologie und Onkologie Faculty of Medicine > Pathologie und Neuropathologie > Institut für Pathologie Faculty of Medicine > Weitere > Centrum für integrierte Onkologie (CIO) |
| Subjects: | Medical sciences Medicine |
| Uncontrolled Keywords: | Keywords Language adjuvant chemotherapy ; FLOT ; gastric adenocarcinoma ; oesophagogastric junction adenocarcinoma ; tumour regression English |
| ['eprint_fieldname_oa_funders' not defined]: | Publikationsfonds UzK |
| Refereed: | Yes |
| URI: | http://kups.ub.uni-koeln.de/id/eprint/80530 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
![]() |
View Item |
https://orcid.org/0009-0006-9275-6121